New type of androgen receptor inhibitors for prostate cancer treatment
New type of androgen receptor inhibitors for prostate cancer treatment
批准号:
7805324
负责人:
Olga B Chernova
金额:
$10.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2011-02-28
关键词:
AblationAndrogen ReceptorAndrogensAntiandrogen TherapyApoptoticBackBicalutamideBindingBiologicalCastrationCell DeathCellsCessation of lifeCharacteristicsChemicalsClinicalDNA DamageDependenceDevelopmentDiseaseDrug Delivery SystemsDrug resistanceEpithelial CellsEvaluationFailureFutureGene AmplificationGoalsHormonesIn VitroLeadLibrariesLifeLigand Binding DomainLigandsMaintenanceMalignant NeoplasmsMalignant neoplasm of prostateMessenger RNAMetabolicMorbidity - disease rateMutateMutationNamesNew AgentsPathway interactionsPharmaceutical PreparationsPhasePopulationPreclinical TestingProbabilityPropertyProstateProstate Cancer therapyProstatic NeoplasmsRadiationRadiation therapyReceptor GeneReceptor SignalingResistanceRoleSecond Primary CancersSeriesSolubilityStagingStructure-Activity RelationshipTestingTestisTherapeuticTissuesTransactivationWithdrawalandrogen independent prostate cancerbasecancer cellcancer therapychemotherapydrug developmenteffective therapyhormone refractory prostate cancerhormone therapyhuman RIPK1 proteinimprovedin vivoinhibitor/antagonistkillingsmalemortalitynovel therapeuticsoverexpressionphase 1 studypre-clinicalpublic health relevancereceptorreceptor functionsmall moleculesmall molecule librariesstandard of caretranscription factortumortumor progression
中文摘要
描述(由申请人提供):激素难治性前列腺癌(HRPC)是一种危及生命的疾病,目前可用的药物无法治疗,大多数药物针对雄激素与雄激素受体(AR)的相互作用。尽管肿瘤获得雄激素独立性的机制不同,但所有HRPC肿瘤的一个关键特征是AR保持功能活性,并可能起到保护细胞免于凋亡的作用。因此,在本研究中,我们探索了一种抑制AR的新策略,作为杀死雄激素依赖性细胞和HRPC细胞的手段。这项提议的最终目标是开发一种有效的治疗目前无法治愈的前列腺癌的方法。在这一目标的驱动下,在我们的初步研究中,我们确定了AR的小分子抑制剂,其作用机制与AR配体相互作用不同。这些化合物被称为DARNAs,破坏AR mRNA的稳定性,从而完全消除PCa细胞中的AR蛋白。在体外和体内均证明DARNAs是一种安全、特异的抗pca药物,从而证明了我们策略的可行性。第一阶段建议的具体目标是:1。两种DARNA化合物周围小分子文库的合成及其药理优化。我们已经确定了两种不同化学类别的DARNA化合物。虽然它们在体外表现出特异性和有效的杀伤PCa细胞,但它们的药理特性从未得到优化,而且远未达到最佳,包括代谢稳定性低、溶解度低等。在这个特定的目标中,我们将围绕每个DARNAs建立敏感的焦点库。这些化合物库将在第二个特定目标中进行测试,以鉴定具有与DARNAs相似的生物学特性和更好的药理特性的化合物。2. DARNA化合物的构效关系研究,为临床前试验和临床开发鉴定最佳AR抑制剂。在第一个特定目标中合成的小分子文库将通过一系列测试,旨在鉴定具有与DARNAs相似或更好的针对PCa的特定生物活性的化合物,以及适合体内测试的药理特性。为了实现这一目标,可能需要进行几轮的合成和测试(构效关系研究(SAR))。在成功完成这一阶段的研究后,我们计划在项目的第二阶段进行先进的化合物和几种备用化合物的临床前测试和进一步的药物开发,以开发一种新型的抗前列腺癌疗法。
英文摘要
DESCRIPTION (provided by applicant): Hormone refractory prostate cancer (HRPC) is a life threatening disease that cannot be treated with currently available drugs, most of which target interaction of androgen with the androgen receptor (AR). While there are different mechanisms by which tumors acquire androgen independence, a key feature of all HRPC tumors is that the AR remains functionally active and likely serves to protect cells from apoptotic cell death. Therefore in this proposal we explore a new strategy for inhibition of AR as a means to kill both androgen dependent and HRPC cells. The ultimate goal of this proposal is to develop an effective therapy against the currently incurable form of prostate cancer. Driven by this goal, in our preliminary studies we identified small molecule inhibitors of AR that act through mechanisms distinct from AR-ligand interaction. These compounds, named DARNAs, destabilize AR mRNA and therefore completely eliminate AR protein from PCa cells. DARNAs were shown to be safe and specific anti-PCa agents in vitro and in vivo, thus providing proof of the feasibility of our strategy. Specific aims of the Phase 1 proposal are: 1. Synthesis of small molecule libraries around two DARNA compounds for their pharmacological optimization. We have identified two DARNA compounds in different chemical classes. Although they demonstrated specific and effective killing of PCa cells in vitro their pharmacological properties were never optimized and are far from optimal, which includes low metabolic stability, low solubility etc. In this specific aim we will sensitize focus libraries around each of DARNAs. These libraries of compounds will be tested in the second specific aim for the identification of compounds with biological properties similar to DARNAs and better pharmacological characteristics. 2. Structure activity relationship studies of DARNA compounds for identification of the best AR inhibitor for pre-clinical testing and clinical development. Libraries of small molecules synthesized in the first specific aim will be passed through a series of tests aimed to identification of compounds with specific biological activity against PCa similar or better than DARNAs and pharmacological properties suitable for in vivo tests. Several rounds of synthesis and testing (structure-activity relationship studies (SAR) may be required to achieve this goal. Upon successful completion of this Phase of the study we plan to have advanced compounds and several back-up compounds for preclinical testing and further drug development of a new type of anti- prostate cancer therapy in Phase II of the project.
PUBLIC HEALTH RELEVANCE: Development of new agents against prostate cancer (PC) is proposed. PC is the most frequent malignancy in male population and one of the most frequent cancers in general. Disease-related mortality in PC is around 12%, but very high rate of PC makes number of PC related deaths enormous. Treatment options for PC are rather limited due to acquired resistance of PC to hormonal therapy and intrinsic resistance to chemotherapy. The new agents which may be developed as results of these study have the following features: (i) they will be active on all stages of the disease and may be used primarily or as a second line therapy after failure of standard androgen ablation therapy, they may be used alone or in combination with standard of care; (ii) they supposed to be active against PC resistant to castration, hormone withdrawal, chemo- and radiotherapy; (iii) they are specifically targeted against AR expressing PC cells and non-toxic to most of other cells and tissues; (iv) they are safe and do not cause DNA damage and secondary cancers in contrast to radiation and chemotherapy. Altogether, these new properties would change the field of prostate cancer treatment and significantly decrease mortality and morbidity from this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Hematopoietic Conditioning Agents for Treatment of Hematological Diseases
-
批准号:7805312
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2010
-
负责人:Olga B Chernova
-
依托单位:
Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5
-
批准号:7746561
-
项目类别:
-
资助金额:$10.97万
-
财政年份:2009
-
负责人:Olga B Chernova
-
依托单位:
海外基金